[go: up one dir, main page]

WO2011063864A2 - Préparations cosmétiques ou dermatologiques contenant des combinaisons de zingerone et de composés polyéthoxylés - Google Patents

Préparations cosmétiques ou dermatologiques contenant des combinaisons de zingerone et de composés polyéthoxylés Download PDF

Info

Publication number
WO2011063864A2
WO2011063864A2 PCT/EP2010/004557 EP2010004557W WO2011063864A2 WO 2011063864 A2 WO2011063864 A2 WO 2011063864A2 EP 2010004557 W EP2010004557 W EP 2010004557W WO 2011063864 A2 WO2011063864 A2 WO 2011063864A2
Authority
WO
WIPO (PCT)
Prior art keywords
polyethylene glycol
stearate
preparations
ether
cosmetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/004557
Other languages
German (de)
English (en)
Other versions
WO2011063864A3 (fr
Inventor
Stefan Heuser
Sabrina Ahlheit
Marc Winnefeld
Michael WÖHRMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of WO2011063864A2 publication Critical patent/WO2011063864A2/fr
Anticipated expiration legal-status Critical
Publication of WO2011063864A3 publication Critical patent/WO2011063864A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers

Definitions

  • the present invention relates to cosmetic or dermatological dermatological preparations containing active ingredients for the care and protection of the skin, in particular the sensitive skin as well as especially in the foreground standing by intrinsic and / or extrinsic factors aged or aging skin and the use of such agents and Combinations of such active ingredients in the field of cosmetic and dermatological skin care.
  • Exogenous factors such as UV light and chemical noxae can be cumulatively effective and e.g. accelerate or supplement endogenous aging processes.
  • exogenous factors occur, e.g. on the following structural damage and dysfunction in the skin that go beyond the extent and quality of the damage caused by chronological aging: d) visible vascular dilations (telangiectasias, cuperosis);
  • CONFIRMATION COPY e slackness and formation of wrinkles
  • subcutaneous adipose tissue decreases in age, especially in the periphery (e.g., in the face), so that typical aging skin manifestations may occur.
  • the present invention relates in particular to products for the care of naturally aged skin, as well as for the treatment of the consequential damages of photoageing, in particular of the phenomena listed under a) to g).
  • Products for the care of aged skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or derivatives thereof) or vitamin A and / or its derivatives. Their effect on the structural damage, however, is limited in scope. In addition, there are significant difficulties in product development in stabilizing the active ingredients sufficiently against oxidative degradation. In addition, the use of vitamin A acid-containing products often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.
  • the present invention relates to cosmetic preparations capable of stimulating the subcutaneous adipose tissue of aging skin for increased fat synthesis.
  • the object of the present invention was therefore to find ways that avoid the disadvantages of the prior art.
  • the effect of repairing the damage associated with endogenous, chronological and exogenous skin aging and the prophylaxis should be permanent, sustainable and without the risk of side effects.
  • zingiberone stimulates the differentiation of pre-adipocytes into adipocytes and the accumulation of triglycerides in adipocytes.
  • Zingiberone (also zingerone, vanillylacetone, 4- (4-hydroxy-3-methoxyphenyl) butan-2-one) is characterized by the following structure:
  • Zingeron is a substance that is falsely claimed to be found in ginger.
  • zingerone is a substance which is first produced by the degradation of substances found in ginger such as e.g. Gingerols is produced and their occurrence in extracts is a measure of their poor and barely usable quality (Hänsel, Stichler, Pharmacognosia Phytopharmacy, 7th edition, Springer-Verlag, p 617). In fact, economically and biologically meaningful amounts can only be obtained by chemical synthesis.
  • zingerone is completely protonated at a pH of about 5. This is about the pH of healthy skin, and cosmetic and dermatological preparations are also often buffered in the slightly acidic pH range. As a phenol derivative, zingerone is more volatile in this protonated form and therefore smells more easily than at higher pHs.
  • a further object of the present invention was therefore to provide preparations in which potentially unpleasant odor could emanate from zingerone, could be reduced or even prevented, without it becoming necessary to base the pH.
  • the solution of these objects according to the invention consists in cosmetic or dermatological preparations containing combinations of zingerone and surface-active or surface-active polyethoxylated compounds.
  • the invention furthermore relates to the use of combinations of zingerone and surface-active or surface-active polyethoxylated compounds for the preparation of cosmetic or dermatological preparations for the treatment and prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging.
  • the invention further provides for the use of one or more topically or interface-active polyethoxylated compounds for reducing or preventing unpleasant odors caused by zingerone, in particular in cosmetic or dermatological preparations, preferably those which are buffered to a slightly acidic pH.
  • the preparations according to the invention are particularly advantageously in the form of emulsions.
  • Preparations according to the invention which are advantageously in the form of emulsions, contain one or more topically or interfacially active polyethoxylated compounds which, for example, can be advantageously selected from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example:
  • R-0 - (- CH 2 -CH 2 -O-) n -CH 2 -COOH nd n represent a number from 5 to 30, the polyoxyethylene sorbitol fatty acid ester
  • alkyl ether sulfates of the general formula R-O - (- CH 2 -CH 2 -O-) n -SO 3 -H
  • the top- or surface-active polyethoxylated compounds used are selected particularly advantageously from the group of substances having HLB values of 11-18, very particularly advantageously having HLB values of 14.5-15.5, if the O / W emulsifiers have saturated radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers may also be lower or higher.
  • fatty alcohol ethoxylates from the group of ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols). Particularly preferred are:
  • Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isoloureth-12).
  • the ethoxylated alkyl ether carboxylic acid or its salt may advantageously be sodium laureth-11-carboxylate.
  • alkyl ether sulfate sodium laureth 1-4 sulfate can be advantageously used.
  • polyethylene glycol (30) cholesteryl ether can be advantageously used.
  • polyethylene glycol (25) soybean oil has been proven.
  • ethoxylated castor oil compounds such as polyethylene glycol (40) hydrogenated castor oil (INCI: polyethylene glycol (40) hydrogenated castor oil).
  • polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprate / caprinate, polyethylene glycol (20). glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate / cocoate.
  • sorbitan esters from the group of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • Preferred surface or surface-active polyethoxylated compounds for the purposes of the present invention are polyethylene glycol (8) stearate, polyethylene glycol (20) stearate, polyethylene glycol (21) stearate, polyethylene glycol (22) stearate, polyethylene glycol (23) stearate, polyethylene glycol (24 ) stearate, polyethylene glycol (25) stearate, polyethylene glycol (30) stearate, polyethylene glycol (40) stearate, polyethylene glycol (100) stearate, polyethylene glycol (200) stearate, polyethylene glycol (400) stearate, polyethylene glycol (2) stearyl ether, polyethylene glycol (21) sorbitan monostearate, polyethylene glycol (20) ethylene glycol (20) sorbitan monooleate.
  • Cosmetic or dermatological preparations according to the invention preferably contain from 0.001 to 10% by weight, particularly preferably from 0.01 to 1% by weight, of zingiberone, based on
  • Cosmetic or dermatological preparations according to the invention preferably contain 0.001-10% by weight of one or more surface- or interface-active polyethoxylated compounds, based on the total weight of the preparations.
  • Emulsions are advantageous dosage forms in the sense of the present invention, e.g. in the form of a cream, a lotion, a cosmetic milk are advantageous and contain e.g. Fats, oils, waxes and / or other fatty substances, as well as water and one or more emulsifiers, as they are commonly used for such a type of formulation.
  • Medicinal topical compositions according to the present invention usually contain one or more drugs in effective concentration.
  • drugs for the sake of simplicity, reference is made to the clear distinction between cosmetic and medical use and corresponding products to the statutory provisions of the Federal Republic of Germany (for example, Cosmetics Regulation, Food and Medicines Act).
  • the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, it is possible to use as solvent:
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil; Fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty acids with lower C-number alcohols, for example with isopropanol, propylene glycol or glycerol, or lower esters of fatty alcohols with alkanoic acids C number or with fatty acids;
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products ,
  • mixtures of the abovementioned solvents are used.
  • alcoholic solvents water can be another ingredient.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the context of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or or unsaturated, branched and / or unbranched alcohols having a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2 Octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate and synthetic, semi-synthetic and natural mixtures of such esters, eg Jojoba oil.
  • the oil phase can be advantageously selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and the fatty acid triglycerides, namely the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12 to 18 carbon atoms.
  • the fatty acid triglycerides may be selected, for example, advantageously from the group of synthetic, semi-synthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like. Any mixtures of such oil and wax components are advantageous in
  • the aqueous phase of the preparations according to the invention advantageously contains alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethylenglykolmonomethyl- or -monoethylether and analogous products, furthermore low C-number alcohols, eg Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickening agents, which or which can be advantageously selected from the group of silica, aluminum silicates, polysaccharides or their derivatives, e.g.
  • Hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of the so-called carbopols, for example carbopols of types 980, 981, 1382, 2984, 5984, in each case individually or in combination.
  • carbopols for example carbopols of types 980, 981, 1382, 2984, 5984, in each case individually or in combination.
  • Gels used in the present invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickening agent which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels, preferably a polyacrylate.
  • a thickening agent which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels, preferably a polyacrylate.
  • Fixed pins contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters.
  • liquid oils eg paraffin oils, castor oil, isopropyl myristate
  • semi-solid constituents eg petrolatum, lanolin
  • solid constituents eg beeswax, ceresin and microcrystalline Waxes or ozokerite
  • high-melting waxes eg carnauba wax, candelilla wax
  • propellants for sprayable from aerosol containers cosmetic and / or dermatological preparations in the context of the present invention
  • the usual known volatile, liquefied propellants such as hydrocarbons (propane, butane, isobutane) suitable, which can be used alone or in combination with each other.
  • compressed air is advantageous to use.
  • Anti-wrinkle cream (example 6 and 7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Préparations cosmétiques ou dermatologiques contenant des combinaisons de zingerone et de composés polyéthoxylés tensioactifs.
PCT/EP2010/004557 2009-11-27 2010-07-26 Préparations cosmétiques ou dermatologiques contenant des combinaisons de zingerone et de composés polyéthoxylés Ceased WO2011063864A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200910055920 DE102009055920A1 (de) 2009-11-27 2009-11-27 Kosmetische oder dermatologische Zubereitungen enthaltend Kombinationen aus Zingeron und polyethoxylierten Verbindungen
DE102009055920.5 2009-11-27

Publications (2)

Publication Number Publication Date
WO2011063864A2 true WO2011063864A2 (fr) 2011-06-03
WO2011063864A3 WO2011063864A3 (fr) 2012-10-11

Family

ID=42753406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/004557 Ceased WO2011063864A2 (fr) 2009-11-27 2010-07-26 Préparations cosmétiques ou dermatologiques contenant des combinaisons de zingerone et de composés polyéthoxylés

Country Status (2)

Country Link
DE (1) DE102009055920A1 (fr)
WO (1) WO2011063864A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055678A1 (fr) * 2010-10-25 2012-05-03 Unilever Nv Composition photoprotectrice stable
WO2012131072A1 (fr) * 2011-04-01 2012-10-04 L'oreal Utilisation de gingerone ou de dérivés de celui-ci pour réduire ou retarder les signes du vieillissement cutané
EP2861304B1 (fr) 2012-06-15 2018-08-08 Symrise AG Compositions comprenant des agents de promotion de la biosynthèse du hyaluronane

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60181007A (ja) * 1984-02-28 1985-09-14 Miyoko Terakado シヨウガの成分を使用するムダ毛の再成長を止める方法
JP3542665B2 (ja) * 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
DE19845319A1 (de) * 1998-10-01 2000-04-06 Beiersdorf Ag Verwendung von oberflächenaktiven Substanzen zur Stabilisierung von Flavonen, Flavanonen bzw. Flavonoiden, synergistische Gemische aus Flavonen, Flavanonen bzw. Flavonoiden und oberflächenaktiven Substanzen sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
JP4136143B2 (ja) * 1998-12-11 2008-08-20 花王株式会社 脂肪分解促進剤及び痩身用皮膚化粧料
KR100531980B1 (ko) * 2003-05-02 2005-11-30 최준명 한약재 추출물을 함유하는 화장품 조성물 및 그 제조방법
JP2004346046A (ja) * 2003-05-26 2004-12-09 Shin Etsu Chem Co Ltd 化粧料
US8241681B2 (en) * 2005-10-14 2012-08-14 Symrise Ag Synergistic mixtures of bisabolol and ginger extract
US20080069784A1 (en) * 2006-06-30 2008-03-20 Millikin Cheri L Regulation of mammalian keratinous tissue using skin and/or hair care actives
DE102006050984A1 (de) * 2006-10-26 2008-04-30 Henkel Kgaa Leistungsgesteigerte kosmetische Mittel mit Purin und/oder Purinderivaten
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
DE102006060439A1 (de) * 2006-12-19 2008-06-26 Henkel Kgaa Verbesserung der Hautverträglichkeit von hyperämisierenden Wirkstoffen
DE102008009798B4 (de) * 2008-02-18 2018-06-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen in Form von O/W oder W/O-Emulsionen mit einem Gehalt an 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxphenyl)-propan-1-on

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055678A1 (fr) * 2010-10-25 2012-05-03 Unilever Nv Composition photoprotectrice stable
CN103249394A (zh) * 2010-10-25 2013-08-14 荷兰联合利华有限公司 稳定的遮光组合物
JP2013544801A (ja) * 2010-10-25 2013-12-19 ユニリーバー・ナームローゼ・ベンノートシヤープ 安定なサンスクリーン組成物
CN103249394B (zh) * 2010-10-25 2016-04-27 荷兰联合利华有限公司 稳定的遮光组合物
EA024835B1 (ru) * 2010-10-25 2016-10-31 Юнилевер Нв Стабильная солнцезащитная композиция
WO2012131072A1 (fr) * 2011-04-01 2012-10-04 L'oreal Utilisation de gingerone ou de dérivés de celui-ci pour réduire ou retarder les signes du vieillissement cutané
FR2973230A1 (fr) * 2011-04-01 2012-10-05 Oreal Utilisation de gingerone ou de ses derives pour diminuer ou retarder les signes du vieillissement de la peau
JP2014509631A (ja) * 2011-04-01 2014-04-21 ロレアル 皮膚老化の徴候を低減または遅延させるための、ジンゲロンまたはその誘導体の使用
US11602496B2 (en) 2011-04-01 2023-03-14 L'oreal Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing
EP2861304B1 (fr) 2012-06-15 2018-08-08 Symrise AG Compositions comprenant des agents de promotion de la biosynthèse du hyaluronane

Also Published As

Publication number Publication date
DE102009055920A1 (de) 2011-06-01
WO2011063864A3 (fr) 2012-10-11

Similar Documents

Publication Publication Date Title
EP1567143B1 (fr) Amides d'acide anthranilique et leurs derives utilises comme principes actifs cosmetiques et pharmaceutiques
EP3300771B1 (fr) Utilisation d'isosorbidecaprylates/caprates dans des déodorants et des anti-transpirants
EP1915982A1 (fr) Utilisation du 1,2-décanediol pour réduire la concentration du sébum et/ou pour aider à la pénétration des actives dans des régions de la peau, et des compositions cosmétiques et/ou dermatologiques comprenant du 1,2-décanediol
DE10324566A1 (de) Verwendung von Diphenylmethan-Derivaten als Tyrosinase-Inhibitoren
WO2006069953A1 (fr) Emploi de mélanges actifs synergiques de 1,2-alcanediols en tant que préparations permettant de réguler l'hydratation de la peau
DE10324567A1 (de) Verwendung von Diphenylmethan-Derivaten als antimikrobielle Wirkstoffe
WO2011063864A2 (fr) Préparations cosmétiques ou dermatologiques contenant des combinaisons de zingerone et de composés polyéthoxylés
EP1401389A2 (fr) Utilisation de carnitine et/ou d'une ou de plusieurs acyl-carnitines pour realiser des preparations cosmetiques ou dermatologiques destinees a accroitre la biosynthese de ceramide
EP2560605B1 (fr) Combinaisons de principes actifs comprenant un extrait d' ecorce de magnolia et des agents tensioactifs polyethoxylés (peg-40-stearate)
WO2002102338A1 (fr) Carnitine et acylcarnitines destinees au traitement et a la prophylaxie de defauts de pigmentation
DE102012221460A1 (de) Verwendung von Triethylcitrat als Vergällungsmittel für Ethanol
DE102008009798B4 (de) Kosmetische oder dermatologische Zubereitungen in Form von O/W oder W/O-Emulsionen mit einem Gehalt an 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxphenyl)-propan-1-on
WO2011063865A2 (fr) Préparations cosmétiques ou dermatologiques contenant des combinaisons de zingerone et d'esters d'acide citrique tensioactifs
DE102009055917A1 (de) Verwendung von Zingeron gegen Altershaut
DE102009055919A1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Kombinationen aus Zingeron und grenz- oder oberflächenaktiven Polyglycerylverbindungen
WO2013189694A2 (fr) Préparation cosmétique et dermatologique contenant une ou plusieurs substances modulant le gène / la protéine pour le récepteur endo180
DE102004017376A1 (de) Vorbehandlungsmittel für eine Epilation
EP3402455A1 (fr) Préparations cosmétiques contenant du chlorure de benzéthonium et des diols
EP3454830B1 (fr) Emulsions huile dans eau avec des extraits de plante comprenant des isoflavones et des pigments mica
DE19903729A1 (de) Verwendung von oberflächenaktiven Citronensäureestern zur Stabilisierung von Retinoiden, synergistische Gemische aus Retinoiden und oberflächenaktiven Substanzen sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
WO2015055179A1 (fr) Esters d'acide stéroïde-carboxylique, compositions contenant des esters d'acide stéroïde-carboxylique et leur utilisation dans une application localement topique à des fins cosmétiques ou dermatologiques
DE102007032661A1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend ein oder mehrere Apiogalacturonane oder einen oder mehrere Apiogalacturonane enthaltenden Extrakt aus Zostera marina sowie einem Gehalt an einem oder mehreren Emulgatoren
DE10146802A1 (de) Vitaminhaltige Hautpflegeprodukte
DE20318415U1 (de) Kosmetische und dermatologische Emulsionen, enthaltend Kreatin und/oder Kreatinin und Elektrolytkonzentrationen, einer Ionenstärke von mindestens 50 mmol/l
DE202015001783U1 (de) Hautpflegeprodukte mit Hyaluronsäurehydrolysat, Biotin, Soja-Liposomen und Seidenprotein bzw. Seidenpulver

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10737785

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10737785

Country of ref document: EP

Kind code of ref document: A2